{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    11,
    13
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "06",
        "name": "Amendment 06",
        "scope": {
          "id": "bec11630-a10b-4fba-a28f-e0c2b2fe4e9c",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "4ccf6880-90ca-4517-adb5-451aee8303ea",
          "code": {
            "id": "d5465ac5-ecdf-4a59-8a18-50e5ed1f716f",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "cfd6257e-8339-4a2b-8ac4-a26d4756f0cf",
            "type": {
              "id": "06744098-cfd5-4409-986c-5d58acd9ae6b",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "To update the dose modification and toxicity management guidelines for irAEs and clarify the concomitant use of COVID-19 vaccines. The dose modification guidelines were updated as requested by the U.S. Food and Drug Administration (FDA) to harmonize safety information across PD-1/L1 antibody prescribing information.",
        "effectiveDate": "2021-06-25",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3"
        ],
        "previousVersion": "05",
        "newVersion": "06"
      },
      {
        "id": "amend_2",
        "number": "05",
        "name": "Amendment 05",
        "scope": {
          "id": "ab4b5230-7048-4e9b-9c59-1f50914bb896",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "921c6526-d2ac-4749-aed9-844a0d6d7611",
          "code": {
            "id": "d443a489-d078-407c-a50e-0727466f6f28",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "85acf95d-99c1-49eb-b033-567ed3bad8dc",
            "type": {
              "id": "96588cec-1926-4cb4-84c5-9f236a75bd20",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The alpha spending function to control the Type-I error based on information fraction was replaced with one based on specified calendar time fraction (0.76). Due to potential delayed treatment effects that have been observed with immunotherapy, the stratified log-rank test was replaced by a stratified max-combo test for testing the OS and PFS hypotheses in all subjects.",
        "effectiveDate": "2018-03-08",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2"
        ],
        "previousVersion": "04",
        "newVersion": "05"
      },
      {
        "id": "amend_3",
        "number": "04",
        "name": "Amendment 04",
        "scope": {
          "id": "c3b7b272-12d1-42b7-8856-2bbf0767428c",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "f02e2b3c-cc96-4685-a771-224c6489d0c9",
          "code": {
            "id": "566f17dc-eb79-4e23-a865-a8a6d0faa181",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "1c0040e6-2e40-46ea-8cf9-dac942c3c367",
            "type": {
              "id": "595da291-e1a2-4dcc-ae24-ca4e25af4bf7",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary objectives were changed from dual endpoints of OS and PFS to a single endpoint of OS, based on recommendations from emerging data in MK-3475-KEYNOTE-180. The timing of the interim and final analyses was updated in order to wait for more mature OS data and account for a potential delayed separation in survival curves observed in immuno-oncology studies.",
        "effectiveDate": "2017-08-03",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2"
        ],
        "previousVersion": "03",
        "newVersion": "04"
      },
      {
        "id": "amend_4",
        "number": "03",
        "name": "Amendment 03",
        "scope": {
          "id": "8ae03463-42a2-4c15-84a5-cdd2fe3f3a83",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "3a3b91ac-998f-4942-b49e-e1c2e15d74ac",
          "code": {
            "id": "3b7bbd88-e31e-4e61-b140-5edbf1ac55b8",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "ab48fd6f-50d2-402a-8cec-f33f9242ac7e",
            "type": {
              "id": "36cbb65b-53e5-43c1-bf76-f21d1792bf54",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "To extend the enrollment period beyond the Global Cohort to achieve the required sample size of the China Cohort and the number of events to investigate efficacy and safety in Chinese 2L EC subjects.",
        "effectiveDate": "2017-03-29",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2"
        ],
        "previousVersion": "02",
        "newVersion": "03"
      },
      {
        "id": "amend_5",
        "number": "02",
        "name": "Amendment 02",
        "scope": {
          "id": "3ccebf7a-ce76-4ccc-b7b2-104ff6d16740",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "97b050d3-7040-4983-a5e1-83b9c1bed716",
          "code": {
            "id": "04ca9a44-613e-4602-b496-0317428fccc2",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "b9079cc0-ce00-480d-969e-d9f6b1f79b88",
            "type": {
              "id": "0191b40e-09ad-4f18-9166-8146fcf49d0d",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Sections were revised to identify GEP low, intermediate, and high tumors; to describe the development of GEP cut-off “GEP intermediate or high” and/or to describe how the primary, secondary, and exploratory objectives and endpoints will be met and analyzed.",
        "effectiveDate": "2016-12-09",
        "reasonIds": [
          "ar_5_1",
          "ar_5_2"
        ],
        "previousVersion": "01",
        "newVersion": "02"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "STATISTICAL",
        "description": "Statistical",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "EFFICACY",
        "description": "Efficacy",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_2",
        "code": "EFFICACY",
        "description": "Efficacy",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "China",
        "instanceType": "Country",
        "code": "CN"
      },
      {
        "id": "country_2",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 5,
      "countryCount": 2,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2"
      ],
      "regions": [
        "Global",
        "Asia"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "06",
        "effectiveDate": "2021-06-25",
        "summary": "To update the dose modification and toxicity management guidelines for irAEs and clarify the concomitant use of COVID-19 vaccines. The dose modification guidelines were updated as requested by the U.S. Food and Drug Administration (FDA) to harmonize safety information across PD-1/L1 antibody prescribing information.",
        "previousVersion": "05",
        "newVersion": "06",
        "reasons": [
          "Safety",
          "Regulatory",
          "Operational"
        ]
      },
      {
        "number": "05",
        "effectiveDate": "2018-03-08",
        "summary": "The alpha spending function to control the Type-I error based on information fraction was replaced with one based on specified calendar time fraction (0.76). Due to potential delayed treatment effects that have been observed with immunotherapy, the stratified log-rank test was replaced by a stratified max-combo test for testing the OS and PFS hypotheses in all subjects.",
        "previousVersion": "04",
        "newVersion": "05",
        "reasons": [
          "Scientific",
          "Statistical"
        ]
      },
      {
        "number": "04",
        "effectiveDate": "2017-08-03",
        "summary": "The primary objectives were changed from dual endpoints of OS and PFS to a single endpoint of OS, based on recommendations from emerging data in MK-3475-KEYNOTE-180. The timing of the interim and final analyses was updated in order to wait for more mature OS data and account for a potential delayed separation in survival curves observed in immuno-oncology studies.",
        "previousVersion": "03",
        "newVersion": "04",
        "reasons": [
          "Scientific",
          "Efficacy"
        ]
      },
      {
        "number": "03",
        "effectiveDate": "2017-03-29",
        "summary": "To extend the enrollment period beyond the Global Cohort to achieve the required sample size of the China Cohort and the number of events to investigate efficacy and safety in Chinese 2L EC subjects.",
        "previousVersion": "02",
        "newVersion": "03",
        "reasons": [
          "Operational",
          "Regulatory"
        ]
      },
      {
        "number": "02",
        "effectiveDate": "2016-12-09",
        "summary": "Sections were revised to identify GEP low, intermediate, and high tumors; to describe the development of GEP cut-off “GEP intermediate or high” and/or to describe how the primary, secondary, and exploratory objectives and endpoints will be met and analyzed.",
        "previousVersion": "01",
        "newVersion": "02",
        "reasons": [
          "Scientific",
          "Efficacy"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "China",
          "code": "CN"
        },
        {
          "name": "United States",
          "code": "US"
        }
      ],
      "regions": [
        "Global",
        "Asia"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}